Tagged with EU

Denmark Novo Nordisk, Lundbeck, and LEO Pharma are the major players in the Danish pharmaceutical industry, all with significant R&D and manufacturing operations in the country. Made with Visme Infographic Maker Made with Visme Infographic Maker   Moreover, Denmark is the Nordics’ leading exporter of pharmaceuticals, as the below charts show. Made with Visme…

Europe Jasper Kunow, MSD’s managing director for Central Eastern Europe, outlines the threat that cancer still poses to Europe, the challenges of enacting the EU’s Beating Cancer Plan across the CEE region, and how policymakers and payers can help overcome them   “In 2020, while we were all fighting against the…

Denmark On April 16, the Danish government unveiled, to great anticipation and fanfare, a brand-new National Life Science Strategy which seeks to chart the course for the next three years of an industry sector that has become increasingly influential for the country’s economy. Indeed, Denmark’s healthcare and life sciences segment now…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…

Switzerland While once considered the land of milk and honey within Europe in terms of market access and reimbursement for innovative pharmaceuticals, Switzerland is increasingly tightening its belt on this front in line with its European neighbours. Indeed, this year two cost containment packages are under discussion in the Swiss parliament…

Switzerland Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique transcription factor targeting molecule potentially represents a breakthrough in cancer research, the ways in which the firm’s funding strategy has evolved, and how its future growth trajectory might look.…

Switzerland Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the presence of Roche, Novartis, Lonza and many others; explains why biotech companies are choosing to go public at later stages…

Switzerland Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to control appetite, and how it compares with the new generation of obesity treatments coming from Big Pharma. Moreover, he discusses EraCal’s development strategy and the Swiss biotech ecosystem.…

Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production.   2020 was defined by an increase in demand for dietary supplements because…

Switzerland Santen is a leading multinational company that specializes in ophthalmology. President and Head for Europe, Middle East and Africa (EMEA) Luis Iglesias highlights the company’s recent transformation through partnerships across a vast array of areas including digital technology and cell and gene. He also discusses how Santen has leveraged its…

Switzerland Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be an inflection point for phytopharma, and what keeps him motivated after 22 years at the firm.   COVID has led…

Spain The latest from Spanish pharma, including the acquisition of PTS by a private equity group for its nanoparticle drug delivery technologies; the agreement between Esteve and Kowa to license an acute pain product currently in Phase III; and the growth of the Spanish pharma market in February after falling 4…